August 5, 2021

Quarterly Financial Summary(For the first three months of the fiscal year ending March 31, 2022)[Under Japanese GAAP](Consolidated)
Listed Company: Zeria Pharmaceutical Co., Ltd.
(Stock Exchange: First Section of Tokyo Stock Exchange)
Code Number: 4559
(URL: https://www.zeria.co.jp/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division
TEL (03) 3661-1039
Scheduled date to submit the Quarterly Securities Report:
August 10, 2021
Scheduled date to commence dividend payments:–Preparation of supplementary documents to the quarterly financial results:
None
Holding of quarterly financial results presentation:
None(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2021 through June 30, 2021)(1) Consolidated Financial Results (cumulative)(Percentage figures indicate changes from the same period of the previous year.)
Profit attributable toOperating profit
Ordinary profit
owners of parent

Net sales
Three months ended

Million yen%

Million yen%

Million yen%

Million yen%

June 30, 2021

13,548

6.4

1,251

18.3

2,081

229.1

1,408

44.8

June 30, 2020

12,735

–

1,058

–

632

–

972

–

Note: Comprehensive income: For the three months ended June 30, 2021: 211 million yen [(86.1)%]
For the three months ended June 30, 2020: 1,519 million yen [–%]

Basic earnings
per share

Diluted earnings
per share

Three months ended

Yen

Yen

June 30, 2021

30.91

–

June 30, 2020

21.02

–

Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised
ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure for the three months ended June 30,2020, is the figure after retrospectively applying the accounting standard and relevant revised ASBJ regulations. Consequently, the percentageof year-on-year change of each figure for the three months ended June 30, 2020, is not shown.

(2) Consolidated Financial Position
Total assets
As ofNet assets

Equity ratio

Net assets per share

Million yen

Million yen%

Yen

June 30, 2021

123,11054,91244.5

1,207.44

March 31, 2021

121,860

56,15245.9

1,225.09

Reference: Equity: As of June 30, 2021: 54,734 million yen
As of March 31, 2021: 55,985 million yen
Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised
ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure as of March 31, 2021, is the figure
after retrospectively applying the accounting standard and relevant revised ASBJ regulations.

2. Dividends
Annual dividendsFirst quarter

Second quarter

Third quarter

Year-end

Total

Yen

Yen

Yen

YenYen–

17.00

–

17.00

34.00

17.00

–

17.00

34.00

Year ended
March 31, 2021
Year ending
March 31, 2022
Year ending
March 31, 2022
(Forecast)–Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021 through March 31, 2022)(Percentage figures indicate changes from the same period of the previous year.)
Profit attributable toBasic earnings
Operating profit
Ordinary profit
owners of parentper share

Net sales
Million yen%

Million yen%

Million yen%

Million yen%

YenFirst six months

29,000

13.6

2,100

31.4

2,200

68.3

1,500

8.0

33.00

Full year

60,000

13.7

4,800

38.1

4,800

49.6

3,300

5.0

72.70

Note: Revision of the financial forecast most recently announced: None
Year-on-year changes and changes from the same period of the fiscal year are presented in comparison with figures from previous fiscal years after
retrospective adjustments as retrospective adjustments were carried out due to changes in accounting policies.

* Notes(1) Significant changes of subsidiaries during the three months ended June 30, 2021 (changes in specified subsidiaries
resulting in changes in scope of consolidation): None
Inclusion: – (Company name: –)Exclusion: – (Company name: –)(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after
error corrections
1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)
1) Number of shares issued as of the end of the period (including treasury shares):
As of June 30, 2021: 53,119,190 shares
As of March 31, 2021: 53,119,190 shares
2) Number of treasury shares as of the end of the period:
As of June 30, 2021: 7,788,464 shares
As of March 31, 2021: 7,420,461 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the three months ended June 30, 2021: 45,583,769 shares
For the three months ended June 30, 2020: 46,274,694 shares* Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or
An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters
The description about the future including the projection in this document is based on information available to theCompany at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions
herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ
from the information in this document due to various factors.